Cyclacel - which has a CDK inhibitor in P2 - also revealed that their Aurora inhibitor is near IND (CYC116). What's interesting, though, is that in this article (http://biz.yahoo.com/bw/061113/20061113005486.html?.v=1) Cyclacel reveals (I think for the first time) that CYC116 not only inhibits Aurora, but also VEGFR2. This could be a case of limited selectivity being spun as a positive, but if CYC116 is selective for just Aurora and VEGFR2, you'd have an anti-angiogenic cell cycle inhibitor, which would be very interesting, if effective.
Note, Cyclacel also said CYC116 was just about to IND this time last year, and while CYCC has ~$60M in cash on hand, the company's market value is only ~$90M
Showing posts with label CYC116. Show all posts
Showing posts with label CYC116. Show all posts
Subscribe to:
Posts (Atom)